NO171785C - Analogifremgangsmaate for fremstilling av terapeutisk virksomme kinazolinderivater - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk virksomme kinazolinderivater

Info

Publication number
NO171785C
NO171785C NO863980A NO863980A NO171785C NO 171785 C NO171785 C NO 171785C NO 863980 A NO863980 A NO 863980A NO 863980 A NO863980 A NO 863980A NO 171785 C NO171785 C NO 171785C
Authority
NO
Norway
Prior art keywords
preparation
therapeutically effective
alkyl
analogy procedure
chinazoline derivatives
Prior art date
Application number
NO863980A
Other languages
English (en)
Norwegian (no)
Other versions
NO863980D0 (no
NO171785B (no
NO863980L (no
Inventor
Masasji Hashimoto
Teruo Oku
Yoshikuni Ito
Takayuki Namiki
Kozo Sawada
Chiyoshi Kasahara
Yukihisa Baba
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO863980D0 publication Critical patent/NO863980D0/no
Publication of NO863980L publication Critical patent/NO863980L/no
Publication of NO171785B publication Critical patent/NO171785B/no
Publication of NO171785C publication Critical patent/NO171785C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15Six-membered rings
    • C07D285/16Thiadiazines; Hydrogenated thiadiazines
    • C07D285/181,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/201,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/221,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/241,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO863980A 1985-10-07 1986-10-06 Analogifremgangsmaate for fremstilling av terapeutisk virksomme kinazolinderivater NO171785C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858524663A GB8524663D0 (en) 1985-10-07 1985-10-07 Quinazoline derivatives

Publications (4)

Publication Number Publication Date
NO863980D0 NO863980D0 (no) 1986-10-06
NO863980L NO863980L (no) 1987-04-08
NO171785B NO171785B (no) 1993-01-25
NO171785C true NO171785C (no) 1993-05-05

Family

ID=10586291

Family Applications (1)

Application Number Title Priority Date Filing Date
NO863980A NO171785C (no) 1985-10-07 1986-10-06 Analogifremgangsmaate for fremstilling av terapeutisk virksomme kinazolinderivater

Country Status (23)

Country Link
US (2) US4734419A (enExample)
EP (1) EP0218999B1 (enExample)
JP (3) JPS6296476A (enExample)
KR (1) KR940007270B1 (enExample)
CN (1) CN1017242B (enExample)
AT (1) ATE60761T1 (enExample)
AU (1) AU596611B2 (enExample)
CA (1) CA1289139C (enExample)
DE (1) DE3677452D1 (enExample)
DK (1) DK158838C (enExample)
ES (1) ES2021266B3 (enExample)
FI (1) FI90234C (enExample)
GB (1) GB8524663D0 (enExample)
GR (1) GR3001502T3 (enExample)
HK (1) HK6993A (enExample)
HU (1) HU196972B (enExample)
IE (1) IE59309B1 (enExample)
IL (1) IL80213A (enExample)
NO (1) NO171785C (enExample)
SG (1) SG112092G (enExample)
SU (1) SU1588283A3 (enExample)
UA (1) UA5562A1 (enExample)
ZA (1) ZA867043B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
WO1988001270A1 (en) * 1986-08-21 1988-02-25 Pfizer Inc. Pyridopyrimidinediones
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
US4931440A (en) * 1987-07-29 1990-06-05 Fujisawa Pharmaceutical Company, Ltd. Uricosuric composition
US4898867A (en) * 1987-09-16 1990-02-06 Taiho Pharmaceutical Company, Limited Thienopyrimidine derivaties as aldose-reductase inhibitors
JP2621460B2 (ja) * 1988-02-29 1997-06-18 藤沢薬品工業株式会社 利尿または降圧剤
US5324747A (en) * 1992-07-15 1994-06-28 Hoffmann-La Roche Inc. N-substituted anilines, inhibitors of phospholipases A2
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
EP0847382B1 (de) * 1995-08-31 2000-12-20 Clariant GmbH Monoester der carboxymethylenanthranilsäuren und verfahren zu ihrer herstellung
DE19532052C2 (de) * 1995-08-31 1998-11-19 Clariant Gmbh Verfahren zur Herstellung von Chinazolinderivaten
CA2193932C (en) * 1995-12-26 2001-08-21 Shinji Nishii Process for producing isatoic anhydrides
WO1997024335A1 (en) * 1995-12-28 1997-07-10 Fuji Chemical Industry Co., Ltd. Process for the preparation of 3-dihalobenzyl-2,4-quinazolinedione derivatives
DE69701647T2 (de) * 1996-02-01 2000-09-07 Sumitomo Chemical Co., Ltd. Verfahren zur Herstellung von Dioxochinazolinen
DE19650975A1 (de) * 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
ES2363230T3 (es) * 1997-04-15 2011-07-27 Csir Métodos no terapéuticos para suprimir el apetito.
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
TR200002209T2 (tr) 1998-01-30 2000-11-21 R-Tech Ueno, Ltd. Oftalmik bileşim.
WO2000043015A1 (fr) * 1999-01-25 2000-07-27 Fujisawa Pharmaceutical Co., Ltd. Gouttes ophtalmologiques
BR0005010A (pt) 1999-02-18 2002-03-19 R Tech Ueno Ltd Composição para tratamento de distúrbios de secreção externa exceto a hipolacrimação e seu uso
AU2830700A (en) * 1999-03-09 2000-09-28 Fujisawa Pharmaceutical Co., Ltd. Process for producing quinazoline derivative or salt thereof
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
CN1477976A (zh) 2000-11-30 2004-02-25 �Ʒ� Gaba激动剂与醛糖还原酶抑制剂的组合
WO2002098462A1 (en) * 2001-06-01 2002-12-12 Ono Pharmaceutical Co., Ltd. Remedies containing aldose reductase inhibitor as the active ingredient for demyelinating diseases or diseases associated with demyelination
CA2475879A1 (en) * 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis of quinazolinones
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
JP2006508030A (ja) * 2002-05-09 2006-03-09 サイトキネティクス・インコーポレーテッド ピリミジノン化合物、組成物および方法
WO2003097053A1 (en) 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004026226A2 (en) * 2002-05-10 2004-04-01 Cytokinetics, Inc. Compounds, compositions and methods
AU2003265242A1 (en) * 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
US7041676B2 (en) * 2002-06-14 2006-05-09 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003256805A1 (en) * 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
US20040048853A1 (en) * 2002-08-21 2004-03-11 Gustave Bergnes Compounds, compositions, and methods
WO2004034972A2 (en) * 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
WO2005041888A2 (en) * 2003-11-03 2005-05-12 Cytokinetics, Inc. Pyrimidin-4-one compounds, compositions and methods
EP1680420A4 (en) * 2003-11-07 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP1692112A4 (en) * 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
US20070010537A1 (en) * 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
EP2044002B1 (en) * 2006-07-19 2014-04-16 E.I. Du Pont De Nemours And Company Process for making 3-substituted 2-amino-5-halobenzamides
WO2008110551A1 (en) 2007-03-12 2008-09-18 Zadec Aps An anti-diabetic extract of rooibos
WO2008118844A1 (en) 2007-03-23 2008-10-02 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibitors
CN101784515A (zh) * 2007-08-03 2010-07-21 弗·哈夫曼-拉罗切有限公司 作为taar1配体的吡啶甲酰胺和苯甲酰胺衍生物
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
CN102219759B (zh) * 2010-04-16 2013-07-24 中国科学院上海药物研究所 芳基甲酰胺类化合物及其制备方法、药物组合物和用途
WO2012088525A2 (en) 2010-12-23 2012-06-28 The Board Of Regents Of The University Of Texas System Methods for treating copd
AU2014262636A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
JP6434498B2 (ja) 2013-05-10 2018-12-05 ギリアド アポロ, エルエルシー Acc阻害剤及びその使用
WO2014182951A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物
WO2019165195A1 (en) 2018-02-22 2019-08-29 Srivastava Satish Combination therapy for the treatment of cancer
CN111499616B (zh) * 2020-05-07 2022-07-22 盐城工学院 一种芳杂环取代的喹唑啉酮衍生物及其合成方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016166A (en) * 1973-12-14 1977-04-05 Hisamitsu Pharmaceutical Co., Inc. 1-Nitrophenylquinazoline-2,4(1H,3H)-diones
DE2652144A1 (de) * 1976-11-16 1978-05-18 Merck Patent Gmbh Neue chinazolindione
CA1161036A (en) * 1980-05-15 1984-01-24 Masayuki Ishikawa Quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
DE3172006D1 (en) * 1980-05-22 1985-10-03 Masayuki Ishikawa Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
JPS58159480A (ja) * 1982-03-17 1983-09-21 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
DD232702A1 (de) * 1982-09-20 1986-02-05 Adw Ddr Verfahren zur herstellung von 1,2,3,4-tetrahydrochinazolin-2,4-dion-essigsaeuren, deren salzen und estern
US4490374A (en) * 1982-09-30 1984-12-25 Ortho Pharmaceutical Corporation 5,6-Dialkoxy-3,4-optionally substituted-2(1H)quinazolinones, composition and method of use
JPS59186963A (ja) * 1983-04-08 1984-10-23 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives

Also Published As

Publication number Publication date
JPH01131164A (ja) 1989-05-24
FI90234C (fi) 1994-01-10
HU196972B (en) 1989-02-28
ATE60761T1 (de) 1991-02-15
US4734419A (en) 1988-03-29
AU6358986A (en) 1987-04-09
CN86106984A (zh) 1987-05-20
FI863917L (fi) 1987-04-08
GB8524663D0 (en) 1985-11-13
EP0218999A2 (en) 1987-04-22
GR3001502T3 (en) 1992-11-23
NO863980D0 (no) 1986-10-06
DK158838B (da) 1990-07-23
CN1017242B (zh) 1992-07-01
CA1289139C (en) 1991-09-17
JPH05366B2 (enExample) 1993-01-05
SG112092G (en) 1992-12-24
IL80213A0 (en) 1987-01-30
IE59309B1 (en) 1994-02-09
JPS6296476A (ja) 1987-05-02
SU1588283A3 (ru) 1990-08-23
KR870003998A (ko) 1987-05-06
UA5562A1 (uk) 1994-12-28
DK459086A (da) 1987-04-08
ZA867043B (en) 1987-07-29
DK459086D0 (da) 1986-09-25
AU596611B2 (en) 1990-05-10
NO171785B (no) 1993-01-25
EP0218999B1 (en) 1991-02-06
US4883800A (en) 1989-11-28
EP0218999A3 (en) 1988-01-13
JPH01125322A (ja) 1989-05-17
FI863917A0 (fi) 1986-09-29
KR940007270B1 (en) 1994-08-12
JPH0482148B2 (enExample) 1992-12-25
HK6993A (en) 1993-02-05
HUT41747A (en) 1987-05-28
DE3677452D1 (de) 1991-03-14
JPH0794447B2 (ja) 1995-10-11
IL80213A (en) 1991-06-30
IE862520L (en) 1987-04-07
FI90234B (fi) 1993-09-30
ES2021266B3 (es) 1991-11-01
NO863980L (no) 1987-04-08
DK158838C (da) 1991-01-14

Similar Documents

Publication Publication Date Title
NO171785C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme kinazolinderivater
IL107426A0 (en) Heterocyclic compounds, processes for the preparation thereof, and pharmaceutical compositions containing the same
NO166126C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive kinolonkarboksylsyrederivater.
NO163568C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonkarboksylsyrederivater.
NO882334L (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkansulfonanilid-derivater.
NO905620L (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
DK283984D0 (da) Benzodiazepinderivater og fremgangsmaade til fremstilling deraf
ATE143658T1 (de) Pyrrolidin-derivate
DK210387D0 (da) Heterocykliske forbindelser og fremgangsmaade til deres fremstilling samt farmaceutiske midler indeholdende disse

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN APRIL 2003